Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 1, 2009, Pages 79-97

  Hou, Runhua ^a   Goldberg, Anne Carol ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid sequestrants; Efficacy; Ezetimibe; LDL C; Safety; Statins

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOATING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIABETIC PATIENT; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PROTECTION; HEMORRHOID; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID TRANSPORT; LIVER TOXICITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AZETIDINES; BILE ACIDS AND SALTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; NIACIN;

EID: 59949088249     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.11.007     Document Type: Review

References (98)

1. Kannel W.B. Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J 110 5 (1985) 1100-1107
2. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention trial. Diabetes Care 16 2 (1993) 434-444
3. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 3 (1984) 351-364
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 8934 (1994) 1383-1389
5. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 20 (1995) 1301-1307
6. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 14 (1996) 1001-1009
7. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 20 (1998) 1615-1622
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
9. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 2 (2004) 227-239
10. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
11. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
12. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 47 7 (2006) 1339-1351
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
14. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
15. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 14 (2005) 1425-1435
16. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
17. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 13 (2006) 1556-1565
18. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 9 (2004) 1071-1080
19. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33 11 (1992) 1569-1582
20. Istvan E.S., and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 5519 (2001) 1160-1164
21. Bilheimer D.W., Grundy S.M., Brown M.S., et al. Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Trans Assoc Am Physicians 96 (1983) 1-9
22. Arad Y., Ramakrishnan R., and Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 31 4 (1990) 567-582
23. Arad Y., Ramakrishnan R., and Ginsberg H.N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41 5 (1992) 487-493
24. Forster L.F., Stewart G., Bedford D., et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164 1 (2002) 129-145
25. Ooi E.M.M., Barrett P.H.R., Chan D.C., et al. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis 197 1 (2008) 139-146
26. Davidson M.H., Stein E.A., Dujovne C.A., et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 79 1 (1997) 38-42
27. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 7 (1999) 498-511
28. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 97 8A (2006) 6C-26C
29. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 97 8A (2006) 44C-51C
30. Bradford R.H., Shear C.L., Chremos A.N., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 74 7 (1994) 667-673
31. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114 25 (2006) 2788-2797
32. Cohen D.E., Anania F.A., and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 97 8A (2006) 77C-81C
33. Bruckert E., Hayem G., Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19 6 (2005) 403-414
34. Thompson P.D., Clarkson P.M., and Rosenson R.S. An assessment of statin safety by muscle experts. Am J Cardiol 97 8A (2006) 69C-76C
35. Bottorff M.B. Statin safety and drug interactions: clinical implications. Am J Cardiol 97 8A (2006) 27C-31C
36. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106 8 (2002) 1024-1028
37. Kasiske B.L., Wanner C., and O'Neill W.C. National Lipid Association Statin Safety Task Force Kidney Expert Panel. An assessment of statin safety by nephrologists. Am J Cardiol 97 8A (2006) 82C-85C
38. Shepherd J., Hunninghake D.B., Stein E.A., et al. Safety of rosuvastatin. Am J Cardiol 94 7 (2004) 882-888
39. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 3 (1984) 365-374
40. Levy R.I., Brensike J.F., Epstein S.E., et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI type II coronary intervention study. Circulation 69 2 (1984) 325-337
41. Watts G.F., Lewis B., Brunt J.N., et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339 8793 (1992) 563-569
42. Blankenhorn D.H., Nessim S.A., Johnson R.L., et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 23 (1987) 3233-3240
43. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 19 (1990) 1289-1298
44. Kane J.P., Malloy M.J., Ports T.A., et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264 23 (1990) 3007-3012
45. Grundy S.M., Ahrens Jr. E.H., and Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 78 1 (1971) 94-121
46. Shepherd J., Packard C.J., Bicker S., et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 302 22 (1980) 1219-1222
47. Rudling M.J., Reihner E., Einarsson K., et al. Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc Nat Acad Sci USA 87 9 (1990) 3469-3473
48. Beil U., Crouse J.R., Einarsson K., et al. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 31 5 (1982) 438-444
49. Insull Jr. W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99 3 (2006) 257-273
50. Aldridge M.A., and Ito M.K. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 35 7-8 (2001) 898-907
51. Davidson M.H., Dillon M.A., Gordon B., et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159 16 (1999) 1893-1900
52. Hunninghake D.B., Bell C., and Olson L. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia. Metabolism 30 6 (1981) 610-615
53. Insull Jr. W., Toth P., Mullican W., et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 76 10 (2001) 971-982
54. Lyons D., Webster J., Fowler G., et al. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br J Clin Pharmacol 37 1 (1994) 59-62
55. Insull Jr. W., Davidson M.H., Demke D.M., et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis 112 2 (1995) 223-235
56. Vecchio T.J., Linden C.V., O'Connell M.J., et al. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Arch Intern Med 142 4 (1982) 721-723
57. Davidson M.H., Dicklin M.R., Maki K.C., et al. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs 9 11 (2000) 2663-2671
58. Zieve F.J., Kalin M.F., Schwartz S.L., et al. Results of the Glucose-Lowering Effect of Welchol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29 1 (2007) 74-83
59. Donovan J.M., Stypinski D., Stiles M.R., et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 14 6 (2000) 681-690
60. Crouse III J.R. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 83 2 (1987) 243-248
61. Vroonhof K., van Rijn H.J.M., and van Hattum J. Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med 61 1 (2003) 19-21
62. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 14 (2008) 1431-1443
63. Altmann S.W., Davis Jr. H.R., Zhu L.J., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303 5661 (2004) 1201-1204
64. Merck/Schering-Plough. Zetia (ezetimibe) U.S. prescribing information. Available at:. http://www.zetia.com/zetia/shared/documents/zetia_pi.pdf Accessed August 10, 2008
65. Davis H.R., and Veltri E.P. Zetia: inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 14 3 (2007) 99-108
66. Dujovne C.A., Ettinger M.P., McNeer J.F., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 10 (2002) 1092-1097
67. Knopp R.H., Gitter H., Truitt T., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 8 (2003) 729-741
68. Jacobson T.A., Armani A., McKenney J.M., et al. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 99 6A (2007) 47C-55C
69. Neuvonen P.J., Niemi M., and Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80 6 (2006) 565-581
70. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 4 (2000) 459-467
71. Davidson M.H., and Toth P.P. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol 15 4 (2004) 423-431
72. Davidson M.H., Toth P., Weiss S., et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 24 6 (2001) 467-474
73. Denke M.A., and Grundy S.M. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med 155 4 (1995) 393-399
74. Knapp H.H., Schrott H., Ma P., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110 5 (2001) 352-360
75. Pan H.Y., DeVault A.R., Swites B.J., et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 48 2 (1990) 201-207
76. Hunninghake D., Insull Jr. W., Toth P., et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158 2 (2001) 407-416
77. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 19 (2003) 2409-2415
78. Ballantyne C.M., Weiss R., Moccetti T., et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99 5 (2007) 673-680
79. Goldberg A.C., Sapre A., Liu J., et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79 5 (2004) 620-629
80. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 22 (2001) 1583-1592
81. Kashyap M.L., McGovern M.E., Berra K., et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89 6 (2002) 672-678
82. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 2 (2007) 432-437
83. Zhao X.Q., Morse J.S., Dowdy A.A., et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment study). Am J Cardiol 93 3 (2004) 307-312
84. Jacobson T.A., and Amorosa L.F. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol 73 14 (1994) 25D-29D
85. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95 4 (2005) 462-468
86. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 1 (2005) 120-122
87. Bays H., Rhyne J., Abby S., et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 22 11 (2006) 2191-2200
88. Guyton J.R., Brown B.G., Fazio S., et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 51 16 (2008) 1564-1572
89. Merck. MEVACOR U.S. prescribing information. Available at:. http://www.merck.com/product/usa/pi_circulars/m/mevacor/mevacor_pi.pdf Accessed August 10, 2008
90. Merck. ZOCOR (simvastatin): US prescribing information. Available at:. http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf Accessed August10, 2008
91. Pfizer. Lipitor (atorvastatin calcium): US prescribing information. Available at:. http://media.pfizer.com/files/products/uspi_lipitor.pdf Accessed August 10, 2008
92. Bristol-Myers-Squibb. PRAVACHOL (pravastatin sodium): US prescribing information. Available at:. http://packageinserts.bms.com/pi/pi_pravachol.pdf Accessed August 10, 2008
93. Novartis. Lescol, Lescol XL, (fluvastatin sodium) prescribing information. Available at:. http://www.pharma.us.novartis.com/product/pi/pdf/Lescol.pdf Accessed August 10, 2008
94. AstraZeneca, CRESTOR (rosuvastatin calcium): US prescribing information. Available at:. http://www1.astrazeneca-us.com/pi/crestor.pdf Accessed August 10, 2008
95. Merck/Schering-Plough, U.S. prescribing information for Vytorin. Available at:. http://www.vytorin.com/vytorin/shared/documents/vytorin_pi.pdf Accessed August 14, 2008
96. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 2 (2003) 152-160
97. Bellosta S., Paoletti R., and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 23 (2004) III50-III57
98. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94 9 (2004) 1140-1146